Data as of .
BIOY vs XLVI: which paid, and which earned it?
BIOY and XLVI both write options for income.
What they hold in common
By the books each fund has filed, BIOY and XLVI hold 0% of their money in the same securities at the same weight.
| Only in BIOY | Only in XLVI |
|---|---|
| Treasury Bill 100.00% | STATE STREET HEALTH CARE SELEC 100.46% |
| SSI US GOV MONEY MARKET CLASS 0.40% | |
| STATE STREET HEALTH CARE SELEC OCT26 173 CALL -0.02% | |
| STATE STREET HEALTH CARE SELEC OCT26 170 CALL -0.04% | |
| STATE STREET HEALTH CARE SELEC OCT26 172 CALL -0.80% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and Sep 18, 2026.
Performance, window by window
| Window | Total return | Cash paid | Against the benchmark | |||
|---|---|---|---|---|---|---|
| BIOY | XLVI | BIOY | XLVI | BIOY | XLVI | |
| 3 months | +2.5% | +6.9% | 14.1% | 3.1% | −9.0 pts | −6.3 pts |
| 6 months | not published | +12.2% | not published | 6.4% | not published | −4.6 pts |
| 1 year | not published | +17.9% | not published | 13.0% | not published | −6.7 pts |
| Since launch | +2.0% | +21.1% | 20.6% | 14.7% | −15.3 pts | −6.5 pts |
| BIOY GraniteShares YieldBOOST Biotech ETF Synthetic covered call on XBI, paying weekly | XLVI State Street(R) Health Care Select Sector SPDR(R) Premium Income ETF Covered call on XLV, paying monthly | |
|---|---|---|
| Issuer | GraniteShares | State Street |
| Strategy | synthetic covered call | covered call |
| Benchmark | Biotech (XBI), used as the proxy | Health care sector (XLV) |
| Pays | weekly | monthly |
| Payout rate, annualized | 60.0% | 13.1% |
| Expense ratio | 1.07% | 0.35% |
| Cash paid, 1 year | 20.6% (since launch on May 5, 2026) | 13.0% |
| Price change, 1 year | −19.0% | +4.0% |
| Total return, 1 year | +2.0% (since launch on May 5, 2026) | +17.9% |
| Benchmark return, 1 year | +17.3% | +24.6% |
| Ahead or behind | −15.3 pts | −6.7 pts |
| Return of capital, latest estimate | 96% | not published |
| Age | 136 days | 415 days |
| Net assets | $1m | $27m |
BIOY in plain words
Over the period since launch on May 5, 2026 to Sep 18, 2026, BIOY paid 20.6% of its starting value in cash distributions while its price fell 19.0%. With every distribution reinvested, the fund returned +2.0%. Biotech (XBI), used as the proxy returned +17.3% over the same days, so a holder was behind by 15.3 pts. At its price on Sep 18, 2026 the latest distribution annualizes to 60.0%, paid weekly. GraniteShares estimates that 96% of the distribution paid Aug 25, 2026 was a return of capital (19a-1 notice, estimated, a tax characterization rather than a measure of erosion).
XLVI in plain words
Over the year to Sep 18, 2026, XLVI paid 13.0% of its starting value in cash distributions while its price rose 4.0%. With every distribution reinvested, the fund returned +17.9%. Health care sector (XLV) returned +24.6% over the same days, so a holder was behind by 6.7 pts. At its price on Sep 18, 2026 the latest distribution annualizes to 13.1%, paid monthly.
Questions people ask
- Which is cheaper, BIOY or XLVI?
- BIOY charges 1.07% a year and XLVI charges 0.35%, so XLVI is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, BIOY against XLVI, data as of Sep 18, 2026. https://etfiq.com/compare/income/bioy-vs-xlvi Free to use with attribution; the underlying files are at Open data.